DE19706357A1 - Use of mixtures of plant phospholipid(s) with oils rich in docosa-hexanoic acid and/or eicosa-pentanoic acid - Google Patents
Use of mixtures of plant phospholipid(s) with oils rich in docosa-hexanoic acid and/or eicosa-pentanoic acidInfo
- Publication number
- DE19706357A1 DE19706357A1 DE19706357A DE19706357A DE19706357A1 DE 19706357 A1 DE19706357 A1 DE 19706357A1 DE 19706357 A DE19706357 A DE 19706357A DE 19706357 A DE19706357 A DE 19706357A DE 19706357 A1 DE19706357 A1 DE 19706357A1
- Authority
- DE
- Germany
- Prior art keywords
- acid
- mixtures
- docosa
- eicosa
- oils rich
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 title claims abstract description 11
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 title claims abstract description 11
- 239000000203 mixture Substances 0.000 title claims abstract description 6
- 239000003921 oil Substances 0.000 title claims abstract description 5
- 150000003904 phospholipids Chemical class 0.000 title claims abstract description 5
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 title description 5
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract description 10
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims abstract description 10
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract description 6
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims abstract description 4
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims abstract description 4
- 241001465754 Metazoa Species 0.000 claims abstract description 4
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims abstract description 4
- 235000013311 vegetables Nutrition 0.000 claims description 4
- 230000036314 physical performance Effects 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 description 7
- 239000000787 lecithin Substances 0.000 description 7
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940067606 lecithin Drugs 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 description 2
- 239000006014 omega-3 oil Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 101000833181 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Glycerol dehydrogenase 1 Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Die Erfindung bezieht sich auf eine Anwendung von Gemischen pflanzlicher Phospholipide mit Docosahexaensäure- (DHA) und/oder Eicosapentaensäure- (EPA) reichen Ölen bei warmblütigen Tieren zur Steigerung der körperlichen Leistungsfähigkeit.The invention relates to an application of mixtures vegetable phospholipids with docosahexaenoic acid (DHA) and / or eicosapentaenoic acid (EPA) rich oils warm-blooded animals to increase the physical Performance.
Seit vielen Jahren wird pflanzliches Lecithin in der Humandiätetik zur Unterstützung des Lipidstoffwechsels und zur Entlastung der Leber eingesetzt. Aus der Sportmedizin ist der positive Einfluß von Lecithin auf das Herz-Kreislaufsystem sowie auf die Verkürzung von Erholungszeiten nach Belastung bekannt.Vegetable lecithin has been used in the Human dietetics to support lipid metabolism and used to relieve the liver. From sports medicine is the positive influence of lecithin on the cardiovascular system as well as the reduction of recovery times known after loading.
Von den Omega-3-Fettsäuren im allgemeinen sind Wirkungen bekannt wie Förderung der Durchblutung, Senkung der Gefahr von Thrombose, Artheriosklerose und Herzrhythmusstörungen sowie eine stärkere Aktivierung des Glucosetransportes durch Insulin im Muskel, die in gewisser Weise als synergistisch zu den Wirkungen des Lecithins anzusehen sind. DHA und EPA im Speziellen, weisen diesbezüglich eine bis zum 10-fachen höhere Wirksamkeit gegenüber anderen Omega-3-Fettsäuren, wie beispielsweise α-Linolensäure, auf. Einerseits ist der warmblütige Organismus zwar in der Lage, DHA und EPA aus Vorstufen selbst zu synthetisieren. Andererseits wird von der Wissenschaft einheitlich die Meinung vertreten, daß die Mengen der Eigensynthese zum Erreichen physiologischer Wirkungen zu gering sind und eine ergänzende Zufuhr über die Nahrung notwendig ist.Effects of the omega-3 fatty acids in general known as promoting blood circulation, lowering the risk of thrombosis, atherosclerosis and irregular heartbeat as well as a stronger activation of the glucose transport through Insulin in the muscle, which in some ways is considered synergistic regarding the effects of lecithin. DHA and EPA in particular, show up to 10 times in this regard higher effectiveness compared to other omega-3 fatty acids, such as for example α-linolenic acid. On the one hand is the Warm-blooded organism is able to make DHA and EPA Synthesize precursors yourself. On the other hand, from of science consistently believe that the Amounts of self synthesis to achieve physiological Effects are too small and a supplementary intake via the Food is necessary.
Überraschend wurde nun herausgefunden, daß insbesondere die Mischung aus pflanzlichen Phospholipiden, wie zum Beispiel Rapslecithin, Phosphatidylcholin angereicherte Fraktionen (z. B. Epikuron 135 F), enzymatisch hydrolisierte Lecithine (z. B. Emulfluid E), standardisierte Sojalecithine (z. B. Topcithin 300) mit Docosahexaensäure- (DHA) und/oder Eicosapentaensäure- (EPA) reichen Ölen, wie zum Beispiel Fischölen, Algen- oder bestimmten Pflanzenölen oder -extrakten, in Verhältnissen von 8 : 2 bis 2 : 8, übertragende Wirkungen auf das Ausdauerpotential, auf die Energieverfügbarkeit, auf die Verkürzung der Erholungszeiten nach Belastungen sowie auf die Hyperkompensation (Trainingseffekt) unter Entlastung der Leber bei warmblütigen Tieren hat.It has now surprisingly been found that in particular the Mixture of vegetable phospholipids, such as Rapeseed lecithin, phosphatidylcholine-enriched fractions (e.g. Epikuron 135 F), enzymatically hydrolyzed lecithins (e.g. Emulfluid E), standardized soy lecithins (e.g. Topcithin 300) with docosahexaenoic acid (DHA) and / or Eicosapentaenoic acid (EPA) rich oils, such as Fish oils, algae or certain vegetable oils or extracts, in ratios of 8: 2 to 2: 8, broadcasting Effects on endurance potential on the Energy availability, on the reduction of recovery times after stresses as well as on hyper compensation (Training effect) while relieving the liver warm-blooded animals.
Am Beispiel der Mischung eines standardisierten Sojalecithins (z. B. Topcithin 300) mit Fischöl im Verhältnis 1 : 1 in der Fütterung von Sportpferden konnte gezeigt werden, daß im Vergleich zu einfachem Pflanzenöl (z. B. Sojaöl) und einer Kontrollration ohne Fettergänzung der Glucosegehalt im Blut (schnellverfügbare Energiereserve, Hyperkompensation), der Gesamtproteingehalt im Blut (weniger glucoplastische Aminosäuren zur Energiegewinnung herangezogen) und der Säuren-Basen-Überschuß im Blut erhöht (schnellerer Abtransport von Lactat aus der Muskulatur), der Triglyceridegehalt im Blut (stärkere Spaltung von Triglyceriden zur Energiegewinnung) und die Gesamtbilirubin- und GLDH-Werte im Blut gesenkt (geringere Beeinträchtigung der Leberfunktion) waren.Using the example of a standardized mixture Soy lecithins (e.g. Topcithin 300) in relation to fish oil 1: 1 in the feeding of sport horses could be shown that compared to simple vegetable oil (e.g. soybean oil) and a control ration without fat supplement the glucose content in the Blood (quickly available energy reserve, hyper compensation), the total protein content in the blood (less glucoplastic Amino acids used for energy generation) and the Acid-base excess in the blood increased (faster Removal of lactate from the muscles), the Triglyceride content in the blood (greater cleavage of Triglycerides for energy) and the total bilirubin and blood GLDH levels decreased (less impairment liver function).
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19706357A DE19706357A1 (en) | 1997-02-19 | 1997-02-19 | Use of mixtures of plant phospholipid(s) with oils rich in docosa-hexanoic acid and/or eicosa-pentanoic acid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19706357A DE19706357A1 (en) | 1997-02-19 | 1997-02-19 | Use of mixtures of plant phospholipid(s) with oils rich in docosa-hexanoic acid and/or eicosa-pentanoic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE19706357A1 true DE19706357A1 (en) | 1998-08-27 |
Family
ID=7820704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19706357A Pending DE19706357A1 (en) | 1997-02-19 | 1997-02-19 | Use of mixtures of plant phospholipid(s) with oils rich in docosa-hexanoic acid and/or eicosa-pentanoic acid |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE19706357A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0678247A1 (en) * | 1994-04-18 | 1995-10-25 | The Iams Company | Pet food product containing omega-6 and omega-3 fatty acids |
| DE4301736C2 (en) * | 1992-01-23 | 1996-10-31 | Woobang Land Co | Feed for ruminants for the production of meat enriched with n-3 fatty acids |
-
1997
- 1997-02-19 DE DE19706357A patent/DE19706357A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4301736C2 (en) * | 1992-01-23 | 1996-10-31 | Woobang Land Co | Feed for ruminants for the production of meat enriched with n-3 fatty acids |
| EP0678247A1 (en) * | 1994-04-18 | 1995-10-25 | The Iams Company | Pet food product containing omega-6 and omega-3 fatty acids |
Non-Patent Citations (1)
| Title |
|---|
| HERTRAMPF, J.W.: "Die Mühle + Mischfuttertechnik",133. Jg. (40), Okt. 1996, 658-661 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Alvarez et al. | Lipids in pharmaceutical and cosmetic preparations | |
| DE3687347T2 (en) | FAST-ACTING, INTRAVENOUS EMULSIONS OF OMEGA-3 FATTY ACID ESTERS. | |
| Tripathi et al. | Linseed and linseed oil: health benefits-a review | |
| Bowen-Forbes et al. | Fats | |
| DE69834663T3 (en) | Method of modifying the nutritional composition of the milk secreted by milk-giving animals | |
| CN108651635A (en) | Has effects that the nutrition-balanced health-care edible oil of brain boosting and supplementing | |
| DE19706357A1 (en) | Use of mixtures of plant phospholipid(s) with oils rich in docosa-hexanoic acid and/or eicosa-pentanoic acid | |
| EP1589829A2 (en) | Dietary foodstuff for positively influencing cardiovascular health | |
| CN109673802A (en) | A kind of phosphatidylserine fructus alpiniae oxyphyllae pressed candy and preparation method and application | |
| CN106260120B (en) | A kind of selenium-rich edible blend oil and preparation method thereof | |
| DE69005298T2 (en) | MEDICINAL LIPID COMPOSITION FOR PARENTERAL FOOD. | |
| CN107183219A (en) | A kind of low temperature nutrient blend oil and preparation method thereof | |
| DE3924607A1 (en) | Diet food contg. omega-3-fatty acid, omega-6-fatty acid - with sodium ions and potassium ions, reducing risk of heart and circulation disease | |
| Mehta et al. | Health aspects of Chia seeds (Salvia hispanica L.)-an overview | |
| Elsedeg | Feeding Poultry for Special Purpose: Omega-3 Polyunsaturated Fatty Acid Table Eggs as Functional Food: A Review Article | |
| CN102802428A (en) | Copepod oil composition, formulations comprising the oil composition, and the use thereof to reduce accumulation of visceral fat, improve glucose tolerance, and prevent or treat obesity related diseases and disorders | |
| CA2800438C (en) | Full spectrum fatty acid nutritional supplement | |
| CN101190248B (en) | Long chain fatty milk in camelina sativa oil orally-administered or injection preparations | |
| Mychailo et al. | TENDENCIES OF ENRICHMENT OF FUNCTIONAL MEAT-CONTAINING PRODUCTS | |
| Zh et al. | DETERMINATION OF THE CONTENT OF FATTY ACIDSIN FLAX SEEDS | |
| Abdelrahman et al. | Serum Lipids Profile and Production Performance of Broiler Chicken fed Nilotic Silver Cat Fish Oil Supplemented Diet Badr Hassabelrasoul Eljack, Nagah Abdelwahab Ahmed, Efadil Ahmed Adam, Najwa | |
| JP2004277336A (en) | Preventive ameliorant for cellulite | |
| Björntorp et al. | Fatty acid composition of lipids of serum and aorta in the chicken on different diets | |
| Ruiter | Fischreiche Ernährung in Beziehung zu cardiovasculären Erkrankungen und Serumcholesterolgehalt | |
| CN114698698A (en) | Medical fat component formula food and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law |